A Phase 2 interventional study of Frexalimab and Placebo in Type 1 Diabetes Mellitus, sponsored by Sanofi. Active, not recruiting at 79 sites in 16 countries. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Diabetes Mellitus, Type 1 by Sanofi — 6 open to participants now, 10 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Sanofi.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, this one is the 20th largest by enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 2, and was the 58th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →6 of the 67 studies in Diabetes Mellitus, Type 1 by Sanofi are open now, in 12 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Germany, Israel and 1 more country
Sanofi · Sites in Belgium, France, Germany and 3 more countries
Sanofi · Sites in Kuwait, Saudi Arabia, United Arab Emirates
Ages 18 mo–18 yrs · Healthy volunteers
Sanofi · Sites in United States
Ages 8+
Sanofi · Sites in United States, Argentina, Australia and 17 more countries
Ages 1–25
By country, each count listing its studies:
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 12 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 6 · Phase 3 20 · Phase 4 14
First in 2001; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 197 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 86 across the 60 interventional studies, 194 across the 6 observational. Of the 56 that completed or were terminated, 13 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
5 of the studies in Diabetes Mellitus, Type 1 by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04598893Provention Bio, a Sanofi CompanyRecent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension) | 2026-11 |
| NCT07457580SanofiReal-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) | 2026-11-30 |
| NCT06111586SanofiFrexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS) | 2027-04-28 |
| NCT06812988SanofiTreatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule | 2027-04-29 |
| NCT07038473SanofiEarly Detection of Type 1 Diabetes in First Degree Relatives of Type 1 Diabetes Patients (DETECT T1D GULF) | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 67 studies in Diabetes Mellitus, Type 1 by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, parallel group, double-blind Phase 2 study with a blinded extension evaluating the safety and efficacy of 3 dose levels of frexalimab in comparison with placebo in participants with newly diagnosed T1D on insulin treatment.
Study details include:
Screening period: at least 3 weeks and up to 5 weeks. Enrollment date of the participant must take into consideration this constraint)
Double-blind treatment period 104 weeks:
Main treatment period: 52 weeks Blinded extension: 52 weeks Optional OLE period: 104 weeks Safety follow-up: 26 weeks The treatment duration will be up to 104 weeks , the total study duration will be up to 135 weeks for Part A and Part B.
If participants enter the OLE period, the treatment duration will be up to approximately 208 weeks , and the total study duration will be 240 weeks approximately .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Receiving at least one of the following T1D standard of care (SOC), insulin hormone replacement therapy
Participants must be positive for at least 1 of the following T1D autoantibodies confirmed by medical history and/or obtained at study screening:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Frexalimab · Drug: Insulin
Drug: Frexalimab · Drug: Insulin
Drug: Frexalimab · Drug: Insulin
Matching Placebo
Drug: Placebo · Drug: Insulin
IV Infusion at Day 1 SC Injection from W2 to W102
IV Infusion at Day 1 SC Injection from W2 to W102
SC injection, dose and frequency will be established and/or adjusted by investigator
Change in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC from baseline to W52 for Part B (12-21 y.o.)
mixed meal tolerance test (MMTT) stimulated C-peptide concentration is to be calculated from AUC
Time frame: Baseline to Week 52
Time in range (70-180 mg/dL), assessed by CGM at W52 and W104(part B)
Time frame: At Week 52 and Week 104
Proportion of participants who remain C-peptide positive (mean 2h MMTT stimulated C-peptide concentration ≥0.2 nmol/L) at W52 and W104(part B)
mixed meal tolerance test (MMTT) stimulated C-peptide concentration is to be calculated from AUC
Time frame: At Week 52 and Week 104
Proportion of participants with reduction from baseline to W52 and W104 of less than 10% in mean 2h MMTT stimulated C-peptide concentration(part B)
mixed meal tolerance test (MMTT) stimulated C-peptide concentration is to be calculated from AUC
Time frame: From baseline to Week 52 and Week 104
Proportion of participants with partial remission at W52 and W104 (defined as IDAA1c score ≤9.0, where it is calculated as HbA1c [%] + 4x insulin dose [IU/kg/day])(part B)
Time frame: At Week 52 and Week 104
Change from baseline to W52 and W104 in insulin dose [IU/kg/day](part B)
Time frame: From baseline to Week 52 and Week 104
HbA1c level at Week 52 and Week 104(part B)
Time frame: at Week 52 and Week 104
Proportion of participants with HbA1c ≤6.5% and requiring no injections of exogenous insulin at W52 and W104(part B)
Time frame: At Week 52 and Week 104
Proportion of participants with HbA1c ≤6.5% and requiring ≤0.25 IU of insulin at W52 and W104(part B)
Time frame: At Week 52 and Week 104
Proportion of participants with HbA1c <7% at W52 and W104(part B)
Time frame: At Week 52 and Week 104
Incidence of treatment emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and TEAEs leading to treatment discontinuation
Time frame: Until Week 130
Number of participants with at least one hypoglycemic event
Time frame: Until Week 130
Number of participants with at least one hyperglycemic episode
Time frame: Until Week 130
Number of participants with at least one diabetic ketoacidosis (DKA) event
Time frame: Until Week 130
Number of participants with clinically significant changes in vital signs, electrocardiogram (ECG), and/or laboratory evaluation
Time frame: Until Week 130
Height and growth rate over time (for participants <18 y.o. at screening)
Time frame: Until Week 130
Frexalimab plasma concentrations over time
Time frame: Until Week 104
Incidence of anti-drug antibodies (ADAs) over time
Time frame: Until Week 130
Change from baseline to W52 and W104 in PedsQL Diabetes Symptoms domain score (all participants≥8 y.o.) (part B)
Time frame: From baseline to Week 52 and Week 104
Change from baseline to W52 and W104 in Pediatric Quality of Life (PedsQL) Diabetes Management domain score (all participants≥8 y.o.) (part B)
Time frame: From baseline to Week 52 and Week 104
Change from baseline to W52 and W104 in Problem Areas In Diabetes (PAID) total score (all participants)(part B)
Time frame: From baseline to Week 52 and Week 104
Change from baseline to W52 and W104 in Diabetes Treatment Satisfaction Questionnaires (DTSQs) total and item scores (all participants)(part B)
Time frame: From baseline to Week 52 and Week 104
Change from baseline to W52 and W104 in PAID immediate and theoretical domain scores (caregivers of all participants 12-17 y.o.)(part B)
Time frame: From baseline to Week 52 and Week 104
Change from baseline to W52 and W104 in DTSQs Total and item scores (caregivers of all participants 12-17 y.o.)(part B)
Time frame: From baseline to Week 52 and Week 104
Time in tight range (TITR, 70 - 140 mg/dL), assessed by CGM at W52 and W104(part B)
Time frame: Time in tight range (TITR, 70 - 140 mg/dL), assessed by CGM at W52 and W104
Change from baseline to W104 in mean 2h mixed meal tolerance test (MMTT) stimulated C-peptide concentration, calculated from AUC(part B)
Time frame: From baseline to Week 104
Change from baseline to W52 and W104 in IDAA1c score(part B)
Time frame: From baseline to Week 52
HbA1c level change from baseline to Week 52 and Week 104(part B)
Time frame: From baseline to Week 52 and Week 104
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Dec 2023 (actual). Primary completion is estimated for Apr 2027, 40 months after the start.
Of 51 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 33. This study's planned 40 months is above that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frexalimab